Abbott launches SimpleScreen CRC blood test
Abbott said SimpleScreen CRC joins Cologuard Plus in its colorectal cancer screening portfolio.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Abbott (ABT) Launches FDA-Approved CRC Blood Test
Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for average-risk adults 45+, developed by Freenome and commercialized by Abbott. The test showed 81.1% CRC sensitivity and 90.4% specificity; it is covered by Medicare.Material DetailsContext by AI Analys…
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
ABBOTT PARK, Ill., Sept. 30, 2026 // -- Abbott (NYSE:ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average risk for the disease. Developed and manufactured by…